- Home
- ANTX vs DYAI Comparison
ANTX vs DYAI Comparison
Compare ANTX & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANTX | DYAI |
|---|---|---|
| Founded | 2017 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1M | 30.2M |
| IPO Year | 2022 | 2004 |
Fundamental Metrics
Financial Performance| Metric | ANTX | DYAI |
|---|---|---|
| Price | $1.21 | $0.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.00 | ★ $3.00 |
| AVG Volume (30 Days) | 55.7K | ★ 513.4K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,342,195.00 |
| Revenue This Year | N/A | $12.52 |
| Revenue Next Year | N/A | $92.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.01 | $0.71 |
| 52 Week High | $1.59 | $2.20 |
Technical Indicators
Market Signals| Indicator | ANTX | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 62.34 | 44.24 |
| Support Level | $1.12 | $0.89 |
| Resistance Level | $1.21 | $1.04 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 90.91 | 24.26 |
Price Performance
Historical ComparisonAbout ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.